Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Ringing of the bell.

<< Previous

Bullboard Posts

Next >>

Comment by Yellowknifer69on Feb 08, 2021 3:47pm

194 Views

Post# 32503951

RE:Ringing of the bell.

Wow Kazam - Don't hold back buddy! Tell us how you really feel. LoL

Hey at least you made a profit. You could have bought shares of GME and watched your ship get torpedoed like so many of the Redditors.

Keep your chin up and go spend that paper money Kazam!

Stay Long boys,

Yellowknifer

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario